Cancer and coagulation

American Journal of Hematology

Volumn 87, Issue SUPPL. 1, 2012, Pages

  Khorana, Alok A ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ANTICOAGULANT THERAPY; ARTICLE; CANCER ASSOCIATED THROMBOSIS; CANCER CHEMOTHERAPY; CANCER PATIENT; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; ETHNICITY; HEMATOLOGIC MALIGNANCY; HUMAN; MYELOMA; NEOPLASM; PREVALENCE; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; THROMBOSIS; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; BIOLOGICAL MARKERS; BLOOD COAGULATION; HEPARIN, LOW-MOLECULAR-WEIGHT; HOSPITALIZATION; HUMANS; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; THROMBOEMBOLISM;

EID: 84859974102     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23143     Document Type: Article

References (69)

1. Khorana AA, Francis CW, Culakova E, et al. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer 2007; 110: 2339-2346.
2. Moore RA, Adel N, Riedel E, et al. High incidence of thromboembolic events in patients treated with Cisplatin-based chemotherapy: A large retrospective analysis. J Clin Oncol 2011; 29: 3466-3473.
3. Khorana AA, Dalal M, Lin J, et al. Venous thromboembolism in the cancer outpatient setting: Contemporary rates and predictors in the United States. J Thromb Haemost 2011;O-MO-131.
4. Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100: 3484-3488.
5. Sorensen HT, Mellemkjaer L, Olsen JH, et al. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000; 343: 1846-1850.
6. Khorana AA, Francis CW, Culakova E, et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007; 5: 632-634.
7. Khorana AA. Venous thromboembolism and prognosis in cancer. Thromb Res 2010; 125: 490-493.
8. Elting LS, Escalante CP, Cooksley C, et al. Outcomes and cost of deep venous thrombosis among patients with cancer. Arch Intern Med 2004; 164: 1653-1661.
9. Khorana AA, Connolly GC. Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol 2009; 27: 4839-4847.
10. Reynolds MW, Shibata A, Zhao S, et al. Impact of clinical trial design and execution-related factors on incidence of thromboembolic events in cancer patients: A systematic review and meta-analysis. Curr Med Res Opin 2008; 24: 497-505.
11. Mandala M, Barni S, Floriani I, et al. Incidence and clinical implications of venous thromboembolism in advanced colorectal cancer patients: the 'GISCAD-alternating schedule' study findings. Eur J Cancer 2009; 45: 65-73.
12. Agnelli G, Gussoni G, Bianchini C, et al. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: A randomized, placebo-controlled, double-blind study. Lancet Oncol 2009; 10: 943-949.
13. Agnelli G, George DJ, Fisher W, et al. The ultra-low molecular weight heparin (ULMWH) semuloparin for prevention of venous thromboembolism (VTE) in patients with cancer receiving chemotherapy: SAVE ONCO study. J Clin Oncol 2011 (ASCO Annual Meeting 29:Abstract No: LBA9014 2011).
14. Khorana AA, Kuderer NM, Culakova E, et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111: 4902-4907.
15. Stender MT, Frokjaer JB, Larsen TB, et al. Preoperative plasma D-dimer is a predictor of postoperative deep venous thrombosis in colorectal cancer patients: A clinical, prospective cohort study with one-year follow-up. Dis Colon Rectum 2009; 52: 446-451.
16. Ay C, Vormittag R, Dunkler D, et al. D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: Results from the Vienna Cancer and Thrombosis Study. J Clin Oncol 2009; 27: 4124-4129.
17. Zwicker JI, Liebman HA, Neuberg D, et al. Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin Cancer Res 2009; 15: 6830-6840.
18. Khorana AA, Francis CW, Menzies KE, et al. Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer. J Thromb Haemost 2008; 6: 1983-1985.
19. Khorana AA, Ahrendt SA, Ryan CK, et al. Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. Clin Cancer Res 2007; 13: 2870-2875.
20. Ay C, Simanek R, Vormittag R, et al. High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: Results from the Vienna Cancer and Thrombosis Study (CATS). Blood 2008; 112: 2703-2708.
21. Vormittag R, Simanek R, Ay C, et al. High factor VIII levels independently predict venous thromboembolism in cancer patients: The cancer and thrombosis study. Arterioscler Thromb Vasc Biol 2009; 29: 2176-2181.
22. Khorana AA, Francis CW, Culakova E, et al. Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol (Off J Am Soc Clin Oncol) 2006; 24: 484-490.
23. Blom JW, Doggen CJ, Osanto S, et al. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005; 293: 715-722.
24. Agnelli G, Bolis G, Capussotti L, et al. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: The @RISTOS project. Ann Surg 2006; 243: 89-95.
25. Kroger K, Weiland D, Ose C, et al. Risk factors for venous thromboembolic events in cancer patients. Ann Oncol 2006; 17: 297-303.
26. Heit JA, Silverstein MD, Mohr DN, et al. Risk factors for deep vein thrombosis and pulmonary embolism: A population-based case-control study. Arch Intern Med 2000; 160: 809-815.
27. Blom JW, Vanderschoot JP, Oostindier MJ, et al. Incidence of venous thrombosis in a large cohort of 66, 329 cancer patients: Results of a record linkage study. J Thromb Haemost 2006; 4: 529-35.
28. Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007; 99: 1232-1239.
29. Nalluri SR, Chu D, Keresztes R, et al. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis. JAMA 2008; 300: 2277-2285.
30. Choueiri TK, Schutz FA, Je Y, et al. Risk of arterial thromboembolic events with sunitinib and sorafenib: A systematic review and meta-analysis of clinical trials. J Clin Oncol 2010; 28: 2280-2285.
31. Starling N, Rao S, Cunningham D, et al. Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy: A report from the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group. J Clin Oncol 2009; 27: 3786-3793.
32. Kasthuri RS, Taubman MB, Mackman N. Role of tissue factor in cancer. J Clin Oncol 2009; 27: 4834-4838.
33. Khorana AA, Ahrendt SA, Ryan CK, et al. Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. Clin Cancer Res 2007; 13: 2870-2875.
34. Khorana AA, Francis CW, Menzies KE, et al. Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer. J Thromb Haemost 2008; 6: 1983-1985.
35. Tilley RE, Holscher T, Belani R, et al. Tissue factor activity is increased in a combined platelet and microparticle sample from cancer patients. Thromb Res 2008; 122: 604-609.
36. Thaler J, Ay C, Weinstabl H, et al. Circulating procoagulant microparticles in cancer patients. Ann Hematol 2011; 90: 447-453.
37. Ay C, Mackman N, Key NS, et al. Microparticle-associated tissue factor activity and occurrence of venous thromboembolism in brain, gastrointestinal and pancreatic cancer. J Thromb Haemost 2011;O-MO-133.
38. Kearney JC, Rossi S, Glinert K, et al. Venous thromboembolism (VTE) and survival in a cancer chemotherapy outpatient clinic: A retrospective chart validation of a VTE prediction model. Blood 2009; 2503 (abstract).
39. Price LH, Nguyen MB, Picozzi VJ, et al. Portal vein thrombosis in pancreatic cancer: Natural history, risk factors and implications for patient management. 2010 Gastrointestinal Cancer Symposium Program and Proceedings Abstract 143, 2010.
40. Ay C, Dunkler D, Marosi C, et al. Prediction of venous thromboembolism in cancer patients. Blood 2010; 116: 5377-5382.
41. Khorana AA, Herman K, Rubens D, et al. A predictive risk score for cancer-associated thrombosis: role of screening in a prospective study. Blood 2010; 3173 (abstract).
42. Mandala M, Clerici M, Corradino I, et al. Incidence, risk factors and clinical implications of venous thromboembolism in cancer patients treated within the context of phase I studies: The 'SENDO experience'. Ann Oncol 2011. Epub ahead of print.
43. Palumbo A, Rajkumar SV, Dimopoulos MA, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008; 22: 414-423.
44. Samama MM, Cohen AT, Darmon J-Y, et al. A comparison of Enoxaparin with placebo for the prevention of venous thromboembolism in acutely ILL medical patients. N Engl J Med 1999; 341: 793-800.
45. Leizorovicz A, Cohen AT, Turpie AG, et al. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004; 110: 874-879.
46. Cohen AT, Davidson BL, Gallus AS, et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: Randomized placebo controlled trial. BMJ 2006; 332: 325-329.
47. Lyman GH, Khorana AA, Falanga A, et al. American society of clinical oncology guideline: Recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007; 25: 5490-5505.
48. Wagman LD, Baird MF, Bennett CL, et al. Venous thromboembolic disease. NCCN. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2008; 6: 716-753.
49. Cohen AT, Tapson VF, Bergmann JF, et al. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): A multinational cross-sectional study. Lancet 2008; 371: 387-394.
50. Kucher N, Koo S, Quiroz R, et al. Electronic alerts to prevent venous thromboembolism among hospitalized patients. N Engl J Med 2005; 352: 969-977.
51. Candelario GD, Francis CW, Panzer R, et al. A computerized prompt for thromboprophylaxis in hospitalized cancer patients. Thromb Res 2010; 126: 32-34.
52. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: A double-blind randomized multicentre trial with venographic assessment. ENOXACAN Study Group. Br J Surg 1997; 84: 1099-1103.
53. McLeod RS, Geerts WH, Sniderman KW, et al. Subcutaneous heparin versus low-molecular-weight heparin as thromboprophylaxis in patients undergoing colorectal surgery: Results of the canadian colorectal DVT prophylaxis trial: A randomized, double-blind trial. Ann Surg 2001; 233: 438-444.
54. Agnelli G, Bergqvist D, Cohen AT, et al. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. Br J Surg 2005; 92: 1212-1220.
55. Akl EA, Terrenato I, Barba M, et al. Low-molecular-weight heparin vs. unfractionated heparin for perioperative thromboprophylaxis in patients with cancer: A systematic review and meta-analysis. Arch Intern Med 2008; 168: 1261-1269.
56. Bergqvist D, Agnelli G, Cohen AT, et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 2002; 346: 975-980.
57. Rasmussen MS, Jorgensen LN, Wille-Jorgensen P, et al. Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: A multicenter randomized open-label study. J Thromb Haemost 2006; 4: 2384-2390.
58. Kakkar VV, Balibrea JL, Martinez-Gonzalez J, et al. Extended prophylaxis with bemiparin for the prevention of venous thromboembolism after abdominal or pelvic surgery for cancer: The CANBESURE randomized study. J Thromb Haemost 2010; 8: 1223-1229.
59. Agnelli G, George DJ, Fisher W, et al. The ultra-low molecular weight heparin (ULMWH) semuloparin for prevention of venous thromboembolism (VTE) in patients with cancer receiving chemotherapy: SAVE ONCO study. J Clin Oncol 2011 (ASCO Annual Meeting 29:Abstract No: LBA9014 2011).
60. Riess UP, Deutschinoff G, Opitz B, et al. A prospective, randomized trial of chemotherapy with or without the low molecular weight heparin (LMWH) enoxaparin in patients (pts) with advanced pancreatic cancer (APC): Results of the CONKO 004 trial. J Clin Oncol [ASCO Annual Meeting Proceedings (Post-Meeting Edition)] 2009; 27: 18s.
61. Maraveyas A, Waters J, Roy R, et al. Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. Eur J Cancer 2011. Epub ahead of print.
62. Palumbo A, Cavo M, Bringhen S, et al. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: A phase III, open-label, randomized trial. J Clin Oncol 2011; 29: 986-993.
63. Gould MK, Dembitzer AD, Doyle RL, et al. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann Intern Med 1999; 130: 800-809.
64. Buller HR, Davidson BL, Decousus H, et al. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003; 349: 1695-1702.
65. Palareti G, Legnani C, Lee A, et al. A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy. Thromb Haemost 2000; 84: 805-810.
66. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 146-153.
67. Akl EA, Barba M, Rohilla S, et al. Low-molecular-weight heparins are superior to Vitamin K antagonists for the long-term treatment of venous thromboembolism in patients with cancer: A cochrane systematic review. J Exp Clin Cancer Res 2008; 27: 21.
68. Carrier M, Le Gal G, Cho R, et al. Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients. J Thromb Haemost 2009; 7: 760-765.
69. Decousus H, Leizorovicz A, Parent F, et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prevention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. N Engl J Med 1998; 338: 409-415.